Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110355 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
A Phase 1 study, sponsored by Kartos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02110355 is a Phase 1 study that has completed, run by Kartos Therapeutics. The registered enrollment target is 31 participants.
The verdict
NCT02110355, a Phase 1 study, has completed, sponsored by Kartos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.
Interventions
- DRUG Trametinib
- DRUG Dabrafenib
- DRUG AMG 232
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-12-19 |
| Est. Completion | 2018-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02110355
The ClinicalTrials.gov registry entry for NCT02110355 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kartos Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trametinib is the first listed.
NCT02110355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02110355 about?
NCT02110355 is a clinical study titled "A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma". Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.
What is the current status of trial NCT02110355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-12-19. Estimated completion is 2018-12-27.
What interventions are being tested in trial NCT02110355?
The interventions under investigation include: Trametinib (DRUG), Dabrafenib (DRUG), AMG 232 (DRUG).
Who is sponsoring clinical trial NCT02110355?
This trial is sponsored by Kartos Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.